CS
GALT icon

Credit Suisse’s Galectin Therapeutics GALT Stock Holding History

Credit Suisse’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,210
Closed -$23K – 4397
2020
Q4 		$23K Buy
+10,210
New +$26.8K ﹤0.01% 4299
2019
Q3 		– Sell
-17,384
Closed -$72K – 4152
2019
Q2 		$72K Sell
17,384
-183,340
-91% -$794K ﹤0.01% 3974
2019
Q1 		$1.03M Buy
+200,724
New +$964K ﹤0.01% 2871
2016
Q3 		– Sell
-60,617
Closed -$89K – 4144
2016
Q2 		$89K Sell
60,617
-979
-2% -$1.44K ﹤0.01% 4077
2016
Q1 		$88K Sell
61,596
-1,389
-2% -$1.86K ﹤0.01% 3839
2015
Q4 		$103K Buy
62,985
+2,373
+4% +$5.44K ﹤0.01% 4069
2015
Q3 		$141K Sell
60,612
-24,994
-29% -$58.9K ﹤0.01% 4042
2015
Q2 		$234K Buy
85,606
+18,569
+28% +$56K ﹤0.01% 4146
2015
Q1 		$226K Sell
67,037
-24,178
-27% -$86.4K ﹤0.01% 4013
2014
Q4 		$316K Buy
91,215
+18,019
+25% +$79.6K ﹤0.01% 4024
2014
Q3 		$368K Buy
73,196
+27,114
+59% +$211K ﹤0.01% 3829
2014
Q2 		$636K Sell
46,082
-18,549
-29% -$231K ﹤0.01% 3664
2014
Q1 		$989K Buy
64,631
+51,777
+403% +$737K ﹤0.01% 3128
2013
Q4 		$104K Buy
+12,854
New +$119K ﹤0.01% 4463

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Credit Suisse's GALT Position: Q1 2021 in Review

Credit Suisse sold out of Galectin Therapeutics (GALT) in Q1 2021, closing a stake of 10,210 shares — an estimated $23K sold.

Credit Suisse first reported a position in GALT in Q4 2013 and held it in 14 quarters. The position peaked at $1.03M in Q1 2019. 75 funds tracked by Wall St. Rank hold GALT as of Q1 2021.

  • Credit Suisse reported no remaining Galectin Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 10,210 Galectin Therapeutics shares in Q1 2021, an estimated $23K.
  • Credit Suisse first reported a position in Galectin Therapeutics in Q4 2013 and held it in 14 quarters.
  • Credit Suisse's Galectin Therapeutics position peaked at $1.03M in Q1 2019.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.